Humira

Botox strength bolsters Allergan ahead of AbbVie takeover

Botox’ continuing strength is central to AbbVie’s rationale for its $63bn takeover of Allergan reducing its reliance on it $20bn flagship immunology drug Humira (adalimumab) which is starting to succumb

Skyrizi, Rinvoq help AbbVie weather Humira slowdown

Slumping sales of AbbVie’s top-selling Humira drug outside the US pegged back sales at the company in the fourth quarter, but its newer products kept it in growth. ... Analysts said the results bode well for AbbVie’s plans to accommodate the slowdown

Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s  Humira (adalimumab) and  Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market

AbbVie creates new aesthetics division amid Allergan takeover

Ahead of the upcoming patent loss of AbbVie’s ageing blockbuster Humira, the Allergan acquisition and now the subsequent division of its aesthetics business will give AbbVie more space to focus

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda showcased a study of the intravenous formulation of Entyvio earlier this year, which positioned it head-to-head with AbbVie’s ageing immunology blockbuster Humira (adalimumab). ... In comparison, 22.5% of patients who received Humira every

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]